Work

DNA-PK, a Pharmacological Target in Cancer Chemotherapy and Radiotherapy?

Year: 2012

Type: article

Abstract: In the search for ways of sensitizing tumor cells to chemotherapy or radiotherapy, the inhibition of DNA repair has recently been proposed as a target of clinical interest.Ionizing radiation, as well as several antitumor drugs, induce the formation of DNA double-strand breaks (DSBs), that are highly damaging to the DNA, leading to cell death and genomic instability.DSBs are mainly repaired by the Non-Homologous End-Joining (NHEJ) process, in which DNA dependent protein kinase (DNA-PK) is the key complex.Consequently, specific DNA-PK inhibitors have been selected and evaluated for sensitizing cells to chemotherapy or radiotherapy.The choice of DNA-PK as a pharmacological target of interest in cancer treatment is discussed.

Source: Journal of Cancer Science & Therapy

DOI: 10.4172/1948-5956.s8-001

Author: Bernard Salles Patrick Calsou

Institutions: Centre National de la Recherche Scientifique, Institut de Pharmacologie et de Biologie Structurale

Language: English

Topic: DNA Repair Mechanisms

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Funders: Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Institut National Du Cancer, Electricité de France